BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37167097)

  • 21. Clinical impact of radioactive iodine dose selection based on the number of metastatic lymph nodes in patients with papillary thyroid carcinoma: A multicenter retrospective cohort study.
    Kwon SY; Kim MH; Kong E; Chong A; Yoo SW; Jeon S; Park SA; Kim DW; Kang SH; Choi JE; Ha JM; Jeong SY; Lee SW
    Clin Endocrinol (Oxf); 2021 Dec; 95(6):901-908. PubMed ID: 34185324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radioactive iodine in low- to intermediate-risk papillary thyroid cancer.
    Zhao H; Gong Y
    Front Endocrinol (Lausanne); 2022; 13():960682. PubMed ID: 36034423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma.
    Sun W; Di L; Chen L; Li D; Wu Y; Xiang J; Zhou S; Sun T
    BMC Surg; 2022 Nov; 22(1):374. PubMed ID: 36324095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.
    Lango M; Flieder D; Arrangoiz R; Veloski C; Yu JQ; Li T; Burtness B; Mehra R; Galloway T; Ridge JA
    Thyroid; 2013 Sep; 23(9):1099-105. PubMed ID: 23421588
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
    Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
    J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer.
    Simões-Pereira J; Ferreira TC; Limbert E; Cavaco BM; Leite V
    Thyroid; 2021 Oct; 31(10):1514-1522. PubMed ID: 34155923
    [No Abstract]   [Full Text] [Related]  

  • 28. Risk Factors Associated With Recurrence and Death in Patients With Tall Cell Papillary Thyroid Cancer: A Single-Institution Cohort Study With Predictive Nomogram.
    Wu SS; Joshi N; Sharrett J; Rao S; Shah A; Scharpf J; Burkey B; Lamarre ED; Prendes B; Siperstein A; Shin J; Berber E; Jin J; Krishnamurthi V; Nasr C; Hong L; Buchberger DS; Woody N; Koyfman SA; Geiger JL
    JAMA Otolaryngol Head Neck Surg; 2023 Jan; 149(1):79-86. PubMed ID: 36454559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guiding the postoperative radioactive iodine-131 therapy for patients with papillary thyroid carcinoma according to the prognostic risk groups: a SEER-based study.
    Yang Y; Gan M; Yi K; Han S; Lin Z; Shi Y; Ming J
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17147-17157. PubMed ID: 37782329
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of thyroglobulin in the lymph nodes recurrence of papillary thyroid carcinoma undergoing total thyroidectomy.
    Xing Z; Qiu Y; Li Z; Zhang L; Fei Y; Zhu J; Su A
    BMC Surg; 2021 Jan; 21(1):53. PubMed ID: 33482804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Completion thyroidectomy may not be required for papillary thyroid carcinoma with multifocality, lymphovascular invasion, extrathyroidal extension to the strap muscles, or five or more central lymph node micrometastasis.
    Beom Heo D; Piao Y; Hee Lee J; Ju SH; Yi HS; Su Kim M; Won HR; Won Chang J; Seok Koo B; Eun Kang Y
    Oral Oncol; 2022 Nov; 134():106115. PubMed ID: 36108524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer.
    Hughes DT; White ML; Miller BS; Gauger PG; Burney RE; Doherty GM
    Surgery; 2010 Dec; 148(6):1100-6; discussion 1006-7. PubMed ID: 21134539
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
    Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
    ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
    Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
    Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Significance of multifocality in papillary thyroid carcinoma.
    Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact factors for the outcome of the first
    Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of adjuvant therapy with radioactive iodine in patients with elevated serum thyroglobulin after neck reoperation due to recurrent papillary thyroid cancer: a monoinstitutional comparative study.
    Weslley Rosario P; Franco Mourão G; Regina Calsolari M
    Endocrine; 2020 Apr; 68(1):144-150. PubMed ID: 31865556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of tumor size and focality with recurrence/persistence in papillary thyroid cancer patients treated with total thyroidectomy along with radioactive-iodine ablation and TSH suppression.
    Khan M; Syed AA; Khan AI; Hussain SR; Urooj N
    Updates Surg; 2018 Mar; 70(1):121-127. PubMed ID: 28550398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.